Objective To evaluate the actual perceptions about combined hormonal contraceptives
(CHCs) use in BRCA mutation carriers in comparison to women from the general population …

Germline mutations in BRCA1 and BRCA2 account for a large proportion of hereditary
breast and ovarian cancers. These tumour suppressor genes, respectively, located in …

Simple Summary Being a healthy carrier of a BRCA1/2 pathogenetic variant is not a
contraindication to hormonal contraception and menopause hormonal therapy; however …

BACKGROUND Increasing numbers of BReast CAncer (BRCA) 1 or 2 pathogenic variant
(PV) carriers, who have an inherited predisposition to breast and ovarian cancer, are being …

Background: The relationship between oral contraceptive (OC) use and breast cancer risk is
highly debated. Recent publications support a slight increase in overall breast cancer risk …

Purpose BRCA mutation carriers have an increased risk of developing breast or ovarian
cancer. Oral contraception (OC) is known to increase breast cancer and reduce ovarian …

Abstract Background BRCA1 and BRCA2 (BRCA) mutation carriers face a high lifetime risk
of developing ovarian cancer. Oral contraceptives are protective in this population; however …

Objective: To determine hormone replacement therapy (HRT) use among women at high
risk for breast cancer and ovarian cancer, before genetic testing for the cancer susceptibility …

Objective To evaluate the actual perceptions of postmenopausal hormone therapy (HT) in
BRCA mutation carriers (BRCAmc) in comparison with women from the general population …

Prophylactic salpingo-oophorectomy is currently the only effective strategy available for
decreasing ovarian cancer risk in BRCA1/2 mutation carriers. Significantly decreased risk of …